Kathryn Westendorf

Kathryn Westendorf

Auto-generated profile, based on publicly available information

Kathryn Westendorf

AbCellera Biologics Inc., Vancouver, BC V5Y0A1, Canada

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 April 2022 in Cell Reports
Verified
Journal Article
Open access
KWKathryn Westendorf
Kathryn Westendorf
SŽStefanie Žentelis
Stefanie Žentelis
LWLingshu Wang
Lingshu Wang
DFDenisa Foster
Denisa Foster
PVPeter Vaillancourt
Peter Vaillancourt
BBBryan C. Barnhart
Bryan C. Barnhart
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-neutralizing monoclonal antibodies (mAbs) can reduce the risk of hospitalization from coronavirus disease 2019 (COVID-19) when administered early. However, SARS-CoV-2 variants of concern (VOCs) have negatively affected therapeutic use of some authorized mAbs. Using a high-throughput B cell screening pipeline, we isolated LY-CoV1404 (bebtelovimab), a highly potent SARS-CoV-2 spike glycoprotein receptor binding domain (RBD)-specific antibody. LY-CoV1404 potently neutralizes authentic SARS-CoV-2, B.1.1.7, B.1.351, and B.1.617.2. In pseudovirus neutralization studies, LY-CoV1404 potently neutralizes variants, including B.1.1.7, B.1.351, B.1.617.2, B.1.427/B.1.429, P.1, B.1.526, B.1.1.529, and the BA.2 subvariant. Structural analysis reveals that the contact residues of the LY-CoV1404 epitope are highly conserved, except for N439 and N501. The binding and neutralizing activity of LY-CoV1404 is unaffected by the most common mutations at these positions (N439K and N501Y). The broad and potent neutralization activity and the relatively conserved epitope suggest that LY-CoV1404 has the potential to be an effective therapeutic agent to treat all known variants.

12 May 2021 in Science Translational Medicine
Verified
Journal Article
Open access
PDF file
BJBryan E. Jones
Bryan E. Jones
PBPatricia Brown-Augsburger
Patricia Brown-Augsburger
KCKizzmekia S. Corbett
Kizzmekia S. Corbett
KWKathryn Westendorf
Kathryn Westendorf
JDJulian Davies
Julian Davies
EFEster Falconer
Ester Falconer
LY-CoV555, a SARS-CoV-2 spike protein–specific antibody, neutralizes SARS-CoV-2 and protects the airways of nonhuman primates against infection.